Catalog4 refs
Crystagen (EDP)
Healing & RecoveryResearch use only
Educational use only. Not medical advice. Verify all information with primary sources and a licensed clinician before use.
Body Map
Overview
Crystagen is a Khavinson bioregulator tripeptide (EDP) identified in thymalin with selective action on thymus tissues. Developed at Russia's St. Petersburg Institute of Bioregulation and Gerontology, it enhances immune function by stimulating normal lymphocyte proliferation while inhibiting tumor cell growth. Research shows effectiveness in normalizing immunity in 82% of elderly patients (vs 56% control) and reducing respiratory infections in athletes by doubling HSP gene expression. It works through epigenetic regulation by influencing gene expression and protein synthesis in immune cells, regulating synthesis of heat-shock proteins, cytokines, and affecting cell differentiation, proliferation, and apoptosis.
Primary Uses
Immune dysfunction normalization in elderly patients
Post-infection immune recovery
Radiation/chemotherapy immune recovery
Athletic immune support and stress resistance
HSP gene expression enhancement
Tumor cell inhibition (K-562 erythromyelosis)
B-cell immune system activation
IL-6 expression normalization
Reduction of respiratory viral infections
Protocol Reference
Dose
10-20 mg daily
Frequency
Once daily for 10-20 consecutive days
Half-life
Minutes (short peptide); effects persist via epigenetic changes
Route
Oral capsules · Injectable (lyophilized)
Evidence
Moderate Research
Research Models
Human
Also in Healing & Recovery